Yüklüyor......
New combinations and immunotherapies for melanoma: latest evidence and clinical utility
Until recently there was no effective systemic therapy for metastatic melanoma. Increased understanding of tumor biology and immune regulation has led to the development of drugs targeting the mitogen-activated protein kinase (MAPK) pathway (BRAF inhibitors and MEK inhibitors) and T-cell regulation...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3752177/ https://ncbi.nlm.nih.gov/pubmed/23997828 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834013499637 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|